Why change our name?

When we founded Alv B, our focus was on creating innovative treatments for cancer in companion animals. Over time, our scientific strategy has matured and our commitment to immunotherapy has deepened. We realised that the name “Alv B” did not convey our focus to people unfamiliar with our story. The new name Immuvera combines “immuno” referring to the immune system and the immunotherapies we are building with “veritas”, the Latin word for truth. It signals our dedication to harnessing the immune system’s power and to pursuing scientific truth.

Aligning our identity with our work

Immuvera is a Norwegian biotech company developing novel, cost-effective cancer treatments for dogs. We believe that studying naturally occurring cancers in dogs can provide valuable insights for human medicine. Our cross-functional team, spanning science, clinical development, technical and regulatory expertise has therapies progressing toward randomized clinical trials in dogs with solid tumors. The name Immuvera better reflects this unique combination of immunotherapy innovation and comparative oncology, and it clarifies our purpose for partners, investors and pet owners.

CEO of Immuvera Therapeutics, Jørund Sollid

“While our name is changing, our mission remains unchanged: to develop innovative immunotherapies that improve the lives of dogs and ultimately contribute to advances in human cancer treatment. We will continue to pursue our research with rigor, collaborate with veterinary clinics and research institutions, and expand our pipeline of immune-based therapies.“

We invite you to join us on this journey. Thank you for supporting us as we become Immuvera Therapeutics.